Other Events ·
Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to advance…
RDPTFRadiopharm Theranostics Ltd
Radiopharm Theranostics received a positive recommendation from its Data Safety and Monitoring Committee to advance its Phase 1 HEAT clinical trial for the radiotherapeutic asset 177Lu-RAD202 to Cohort 4. This move increases the dose level to 180mCi in patients with HER2-positive advanced solid tumors, following a previous announcement of the 130mCi dose level on April 8, 2026. The company highlighted a favorable safety profile observed to date and cited clinical proof-of-concept from a prior diagnostic study involving ten HER2-positive breast cancer patients that demonstrated positive safety and biodistribution. Radiopharm Theranostics operates in the biopharmaceutical industry, developing innovative oncology radiopharmaceuticals for diagnostic and therapeutic applications.